/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Evelo Biosciences Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.30005 -0.1446(-14.46%) EVLO at 04 Dec 2025 04:31 PM Biotechnology
Lowest Today 0.31
Highest Today 0.3699
Today’s Open 0.3589
Prev. Close 0.37
52 Week High 40.00
52 Week Low 0.30
Day’s Range: Low 0.31 High 0.3699
52-Week Range: Low 0.30 High 40.00
1 day return -
1 Week return -
1 month return -
3 month return -
6 month return -
1 year return -
3 year return -
5 year return -
10 year return -

Institutional Holdings

Flagship Ventures Management, Inc. 41.90

FMR Inc 12.92

Harbourvest Partners, LLC 7.67

Fidelity Growth Compy Commingled Pl O 2.41

Fidelity® Growth Company 2.00

Vanguard Group Inc 1.89

Vanguard Total Stock Mkt Idx Inv 1.53

Fidelity® Select Biotechnology 1.43

CS (Lux) Digital Health Equity SB USD 1.41

Alyeska Investment Group, L.P. 1.40

State Treasurer State Of Michigan 1.08

Credit Suisse First Boston (CSFB) 1.06

BlackRock Inc 0.67

Fidelity® Growth Company K6 0.62

Fidelity® Series Growth Company 0.55

Vanguard Institutional Extnd Mkt Idx Tr 0.35

Geode Capital Management, LLC 0.34

iShares Biotechnology ETF 0.33

Alphabet Inc 0.28

Millennium Management LLC 0.20

Susquehanna International Group, LLP 0.14

Fidelity® Extended Market Index 0.14

BlackRock Extended Mkt Composite 0.13

Morgan Stanley - Brokerage Accounts 0.12

BlackRock Extended Equity Market K 0.12

Northern Trust Corp 0.10

Barclays PLC 0.06

Fidelity® NASDAQ Composite Index® 0.06

NT Ext Equity Mkt Idx Fd - NL 0.06

Fidelity® Series Total Market Index 0.05

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.05

iShares Nasdaq US Biotech ETF USD Acc 0.04

Northern Trust Extended Eq Market Idx 0.04

NT Ext Equity Mkt Idx Fd - L 0.04

Fidelity® Total Market Index 0.03

Tower Research Capital LLC 0.02

JPMorgan Chase & Co 0.02

Bank of America Corp 0.01

Citigroup Inc 0.01

UBS Group AG 0.00

Market Status

Strong Buy: 0

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 7.00 M

PB Ratio 3.5113

PE Ratio 0.0

Enterprise Value 23.69 M

Total Assets 64.44 M

Volume 712643

Company Financials

Annual Revenue FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M, FY18:0 0.0M

Annual Profit FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M, FY18:0 0.0M

Annual Net worth FY22:-114527000 -114.5M, FY21:-122176000 -122.2M, FY20:-93666000 -93.7M, FY19:-85662000 -85.7M, FY18:-53854000 -53.9M

Quarterly Revenue Q3/2023:0 0.0M, Q2/2023:0 0.0M, Q1/2023:0 0.0M, Q4/2022:0 0.0M, Q3/2022:0 0.0M

Quarterly Profit Q3/2023:-793000 -0.8M, Q2/2023:-1616000 -1.6M, Q1/2023:null 0.0M, Q4/2022:null 0.0M, Q3/2022:null 0.0M

Quarterly Net worth Q3/2023:-12364000 -12.4M, Q2/2023:-21103000 -21.1M, Q1/2023:-25341000 -25.3M, Q4/2022:-23541000 -23.5M, Q3/2022:-30564000 -30.6M

Fund house & investment objective

Company Information Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 66

Industry Biotechnology

CEO Dr. Balkrishan Gill Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow